ScripBioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq
In VivoThe promise of mRNA therapeutics has been held back by a fundamental physical limitation: lipid nanoparticles containing mRNA are inherently fragile and prone to aggregation when subjected to the mech
ScripPharma executives no longer ask whether AI is important in their industry – that much is certain, and it is already ubiquitous. As Lamine Mbow , global head of discovery research at Boehringer Ingelh
ScripGSK is still in the race to bring an mRNA-based flu vaccine to market after scoring a Phase II trial success. The UK-headquartered firm will now take its candidate, GSK4382276A, into Phase III, thoug